Currently, epidermal growth factor receptor (EGFR) mutation is the most common type of gene mutations detected in Asian populations with lung cancer [3, 4], and EGFR is identified as the therapeutic target of EGFR tyrosine kinase inhibitors (TKIs) [5]. This evidence concerns the gene EGFR and lung carcinoma.